Acadia Healthcare Reports Fourth Quarter 2021 Results
Acadia Healthcare Company (ACHC) announced strong financial results for Q4 and full-year 2021, with revenue reaching $593.5 million, a 10.7% increase from Q4 2020. Adjusted EBITDA was $156.1 million, down slightly from the previous year. Net income was $70.3 million, compared to a significant loss in Q4 2020. The company expects 2022 revenue between $2.55 and $2.60 billion and plans to open new facilities, including a 60-bed children's hospital in Chicago. Acadia maintains strong liquidity with $133.8 million in cash as of year-end 2021.
- Q4 revenue increased to $593.5 million, a 10.7% rise year-over-year.
- Net income for Q4 2021 was $70.3 million, a significant recovery from a loss in 2020.
- Acadia's cash position was strong, with $133.8 million available as of December 31, 2021.
- Plans to add 300 beds in 2022 and open new facilities, addressing unmet needs in behavioral health.
- Adjusted EBITDA decreased to $156.1 million from $157.9 million year-over-year.
- Dependence on PRF with $17.9 million included in Q4 results, affecting overall profitability.
Company Provides Full Year and First Quarter 2022 Guidance
Fourth Quarter Highlights
-
Revenue totaled
$593.5 million -
Same facility revenue increased
10.7% as compared to the fourth quarter of 2020, including an increase in revenue per patient day of7.8% and patient days of2.7% -
Adjusted EBITDA totaled
, which included$156.1 million of income from the$17.9 million Provider Relief Fund (“PRF”) established under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act -
Net income attributable to
Acadia Healthcare Company, Inc. totaled , or$70.3 million per diluted share, and adjusted income from continuing operations attributable to Acadia stockholders totaled$0.77 , or$73.6 million per diluted share, which included$0.81 of income from the PRF established under the CARES Act$0.14 -
Cash flows from operating activities totaled
$97.8 million
Fourth Quarter Results
The Company reported revenue of
Net income attributable to Acadia stockholders for the fourth quarter of 2021 was
For the fourth quarter of 2021, Acadia’s same facility revenue increased
Strategic Investments for Long-Term Growth
“We had a very active fourth quarter with respect to key strategic growth initiatives across our service lines. We announced three new joint venture partnerships, the acquisition of real estate to open new facilities in the
“An important growth objective for Acadia is to identify underserved markets for behavioral health treatment and develop wholly owned de novo facilities that help fill this gap. In line with this strategy, during the fourth quarter, we completed the acquisition of the real estate for three currently non-operational facilities, including one adult hospital, one children’s hospital and an outpatient facility, all located on the north side of
“We also continued to expand our network of comprehensive treatment centers (CTCs), which are designed to address the growing and critical need for medication-assisted treatment for patients dealing with opioid use disorder. During the fourth quarter we opened five new CTCs, bringing the total number to ten CTCs opened in 2021. With the growing recognition and acceptance of the critical need for quality addiction treatment, we plan to open an additional six to ten CTCs in 2022 to address this demand.
“As a leading provider of behavioral health services, we are especially proud to work with leading health systems and hospitals across the country who are looking for a strong partner to help expand behavioral health treatment options in their respective communities. We announced three new joint venture partnerships during the fourth quarter, expanding our market reach to 16 partnerships. Our latest partners include
“We also have continued to expand our operations in high growth markets through select acquisitions that meet the criteria of our disciplined capital allocation framework. On
Cash and Liquidity
Acadia’s balance sheet remains strong with ample liquidity and capital to support its growth strategy. As of
During the fourth quarter, the Company continued its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment Program under the CARES Act. Of the
Financial Guidance
Acadia today established financial guidance for 2022, as follows:
2022
Revenue |
|
|
Adjusted EBITDA |
|
|
Adjusted earnings per diluted share |
|
|
Interest Expense |
|
|
Tax rate |
|
|
Depreciation and amortization expense |
|
|
Stock compensation expense |
Approximately |
|
Operating cash flows, including of CARES Act repayments |
|
|
Expansion capital expenditures |
|
|
Maintenance capital expenditures |
Approximately |
Acadia also established financial guidance for the first quarter of 2022, as follows:
First Quarter 2022
Revenue |
|
|
Adjusted EBITDA |
|
|
Adjusted earnings per diluted share |
|
The Company’s guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses.
Looking Ahead
Osteen added, “We are proud of our performance for 2021 as we continued to execute on the key pathways of our growth strategy with favorable results. We are even more proud of the critical role we play as the leading pure-play provider of behavioral healthcare services and our unwavering commitment to providing safe and quality patient care in Acadia’s facilities across our network. Our primary objective for 2022 is to continue to extend our market reach with a goal to add 300 beds to existing facilities and pursue additional opportunities for de novo facilities, joint venture partnerships and acquisitions. As we witness greater societal acceptance of treatment for mental health and addiction issues and more access to funding support, we see significant opportunities for continued growth for Acadia. Importantly, we have the financial strength to support a strategy that delivers greater value for our patients, the communities we serve, and our stakeholders.”
Conference Call
Acadia will hold a conference call to discuss its fourth quarter financial results at
About Acadia
Acadia is a leading provider of behavioral healthcare services across
Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic, including, without limitation, disruption to the
Condensed Consolidated Statements of Operations |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
(In thousands, except per share amounts) |
||||||||||||||
Revenue | $ |
593,480 |
|
$ |
541,276 |
|
$ |
2,314,394 |
|
$ |
2,089,929 |
|
||||
Salaries, wages and benefits (including equity-based compensation expense of |
|
321,120 |
|
|
301,658 |
|
|
1,243,804 |
|
|
1,154,522 |
|
||||
Professional fees |
|
34,824 |
|
|
29,480 |
|
|
136,739 |
|
|
120,489 |
|
||||
Supplies |
|
23,004 |
|
|
22,213 |
|
|
90,702 |
|
|
87,241 |
|
||||
Rents and leases |
|
9,829 |
|
|
9,387 |
|
|
38,519 |
|
|
37,362 |
|
||||
Other operating expenses |
|
79,076 |
|
|
59,732 |
|
|
301,339 |
|
|
262,272 |
|
||||
Income from provider relief fund |
|
(17,900 |
) |
|
(32,819 |
) |
|
(17,900 |
) |
|
(32,819 |
) |
||||
Depreciation and amortization |
|
28,368 |
|
|
24,958 |
|
|
106,717 |
|
|
95,256 |
|
||||
Interest expense, net |
|
15,573 |
|
|
39,707 |
|
|
76,993 |
|
|
158,105 |
|
||||
Debt extinguishment costs |
|
- |
|
|
3,962 |
|
|
24,650 |
|
|
7,233 |
|
||||
Loss on impairment |
|
- |
|
|
4,751 |
|
|
24,293 |
|
|
4,751 |
|
||||
Transaction-related expenses |
|
3,458 |
|
|
2,162 |
|
|
12,778 |
|
|
11,720 |
|
||||
Total expenses |
|
497,352 |
|
|
465,191 |
|
|
2,038,634 |
|
|
1,906,132 |
|
||||
Income from continuing operations before income taxes |
|
96,128 |
|
|
76,085 |
|
|
275,760 |
|
|
183,797 |
|
||||
Provision for income taxes |
|
24,609 |
|
|
16,432 |
|
|
67,557 |
|
|
40,606 |
|
||||
Income from continuing operations |
|
71,519 |
|
|
59,653 |
|
|
208,203 |
|
|
143,191 |
|
||||
Loss from discontinued operations, net of taxes |
|
- |
|
|
(842,194 |
) |
|
(12,641 |
) |
|
(812,390 |
) |
||||
Net income (loss) |
|
71,519 |
|
|
(782,541 |
) |
|
195,562 |
|
|
(669,199 |
) |
||||
Net income attributable to noncontrolling interests |
|
(1,241 |
) |
|
(1,131 |
) |
|
(4,927 |
) |
|
(2,933 |
) |
||||
Net income (loss) attributable to |
$ |
70,278 |
|
$ |
(783,672 |
) |
$ |
190,635 |
|
$ |
(672,132 |
) |
||||
Basic earnings per share attributable to stockholders: |
||||||||||||||||
Income from continuing operations attributable to |
$ |
0.79 |
|
$ |
0.67 |
|
$ |
2.29 |
|
$ |
1.60 |
|
||||
Loss from discontinued operations | $ |
- |
|
$ |
(9.58 |
) |
$ |
(0.14 |
) |
$ |
(9.25 |
) |
||||
Net income (loss) attributable to |
$ |
0.79 |
|
$ |
(8.91 |
) |
$ |
2.15 |
|
$ |
(7.65 |
) |
||||
Diluted earnings per share attributable to stockholders: |
||||||||||||||||
Income from continuing operations attributable to |
$ |
0.77 |
|
$ |
0.66 |
|
$ |
2.24 |
|
$ |
1.58 |
|
||||
Loss from discontinued operations | $ |
- |
|
$ |
(9.44 |
) |
$ |
(0.14 |
) |
$ |
(9.17 |
) |
||||
Net income (loss) attributable to |
$ |
0.77 |
|
$ |
(8.78 |
) |
$ |
2.10 |
|
$ |
(7.59 |
) |
||||
Weighted-average shares outstanding: | ||||||||||||||||
Basic |
|
89,020 |
|
|
87,952 |
|
|
88,769 |
|
|
87,875 |
|
||||
Diluted |
|
91,038 |
|
|
89,233 |
|
|
90,793 |
|
|
88,595 |
|
||||
|
||||||||
Condensed Consolidated Balance Sheets | ||||||||
(Unaudited) | ||||||||
|
||||||||
|
2021 |
|
|
2020 |
|
|||
(In thousands) |
||||||||
|
||||||||
ASSETS |
||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ |
133,813 |
|
$ |
378,697 |
|
||
Accounts receivable, net |
|
281,332 |
|
|
273,551 |
|
||
Other current assets |
|
79,886 |
|
|
61,332 |
|
||
Current assets held for sale |
|
- |
|
|
1,809,815 |
|
||
Total current assets |
|
495,031 |
|
|
2,523,395 |
|
||
Property and equipment, net |
|
1,771,159 |
|
|
1,622,896 |
|
||
Goodwill |
|
2,199,937 |
|
|
2,105,264 |
|
||
Intangible assets, net |
|
70,145 |
|
|
68,535 |
|
||
Deferred tax assets |
|
3,080 |
|
|
3,209 |
|
||
Operating lease right-of-use assets |
|
133,761 |
|
|
96,937 |
|
||
Other assets |
|
94,965 |
|
|
79,126 |
|
||
Total assets | $ |
4,768,078 |
|
$ |
6,499,362 |
|
||
LIABILITIES AND EQUITY |
||||||||
Current liabilities: | ||||||||
Current portion of long-term debt | $ |
18,594 |
|
$ |
153,478 |
|
||
Accounts payable |
|
98,575 |
|
|
87,815 |
|
||
Accrued salaries and benefits |
|
137,845 |
|
|
124,912 |
|
||
Current portion of operating lease liabilities |
|
23,348 |
|
|
18,916 |
|
||
Other accrued liabilities |
|
126,499 |
|
|
178,453 |
|
||
Derivative instrument liabilities |
|
- |
|
|
84,584 |
|
||
Current liabilities held for sale |
|
- |
|
|
660,027 |
|
||
Total current liabilities |
|
404,861 |
|
|
1,308,185 |
|
||
Long-term debt |
|
1,478,626 |
|
|
2,968,948 |
|
||
Deferred tax liabilities |
|
74,368 |
|
|
50,017 |
|
||
Operating lease liabilities |
|
116,841 |
|
|
84,029 |
|
||
Other liabilities |
|
110,505 |
|
|
133,412 |
|
||
Total liabilities |
|
2,185,201 |
|
|
4,544,591 |
|
||
Redeemable noncontrolling interests |
|
65,388 |
|
|
55,315 |
|
||
Equity: | ||||||||
Common stock |
|
890 |
|
|
880 |
|
||
Additional paid-in capital |
|
2,636,350 |
|
|
2,580,327 |
|
||
Accumulated other comprehensive loss |
|
- |
|
|
(371,365 |
) |
||
Accumulated deficit |
|
(119,751 |
) |
|
(310,386 |
) |
||
Total equity |
|
2,517,489 |
|
|
1,899,456 |
|
||
Total liabilities and equity | $ |
4,768,078 |
|
$ |
6,499,362 |
|
||
Condensed Consolidated Statements of Cash Flows | ||||||||
(Unaudited) | ||||||||
Year Ended |
||||||||
|
2021 |
|
|
2020 |
|
|||
(In thousands) | ||||||||
Operating activities: | ||||||||
Net income (loss) | $ |
195,562 |
|
$ |
(669,199 |
) |
||
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities: | ||||||||
Depreciation and amortization |
|
106,717 |
|
|
95,256 |
|
||
Amortization of debt issuance costs |
|
4,071 |
|
|
12,636 |
|
||
Equity-based compensation expense |
|
37,530 |
|
|
22,504 |
|
||
Deferred income taxes |
|
11,772 |
|
|
53,108 |
|
||
Loss from discontinued operations, net of taxes |
|
12,641 |
|
|
812,390 |
|
||
Debt extinguishment costs |
|
24,650 |
|
|
7,233 |
|
||
Loss on impairment |
|
24,293 |
|
|
4,751 |
|
||
Other |
|
491 |
|
|
1,041 |
|
||
Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||
Accounts receivable, net |
|
2,448 |
|
|
15,340 |
|
||
Other current assets |
|
1,968 |
|
|
9,675 |
|
||
Other assets |
|
(10,770 |
) |
|
1,519 |
|
||
Accounts payable and other accrued liabilities |
|
6,164 |
|
|
41,910 |
|
||
Accrued salaries and benefits |
|
9,755 |
|
|
(10,001 |
) |
||
Other liabilities |
|
(14,940 |
) |
|
18,082 |
|
||
Government relief funds |
|
(38,128 |
) |
|
86,599 |
|
||
Net cash provided by continuing operating activities |
|
374,224 |
|
|
502,844 |
|
||
Net cash provided by discontinued operating activities |
|
253 |
|
|
155,963 |
|
||
Net cash provided by operating activities |
|
374,477 |
|
|
658,807 |
|
||
Investing activities: | ||||||||
Cash paid for acquisitions, net of cash acquired |
|
(139,015 |
) |
|
- |
|
||
Cash paid for capital expenditures |
|
(244,811 |
) |
|
(224,964 |
) |
||
Proceeds from U. |
|
1,511,020 |
|
|
- |
|
||
Settlement of foreign currency derivatives |
|
(84,795 |
) |
|
- |
|
||
Proceeds from sale of property and equipment |
|
3,493 |
|
|
92 |
|
||
Cash paid for purchase of finance lease |
|
(31,401 |
) |
|
- |
|
||
Other |
|
3,142 |
|
|
(13,365 |
) |
||
Net cash provided by (used in) continuing investing activities |
|
1,017,633 |
|
|
(238,237 |
) |
||
Net cash used in discontinued investing activities |
|
- |
|
|
(43,602 |
) |
||
Net cash provided by (used in) investing activities |
|
1,017,633 |
|
|
(281,839 |
) |
||
Financing activities: | ||||||||
Borrowings on long-term debt |
|
425,000 |
|
|
925,000 |
|
||
Borrowings on revolving credit facility |
|
500,000 |
|
|
100,000 |
|
||
Principal payments on revolving credit facility |
|
(330,000 |
) |
|
(100,000 |
) |
||
Principal payments on long-term debt |
|
(7,969 |
) |
|
(41,291 |
) |
||
Repayment of long-term debt |
|
(2,227,935 |
) |
|
(909,785 |
) |
||
Payment of debt issuance costs |
|
(7,964 |
) |
|
(18,295 |
) |
||
Common stock withheld for minimum statutory taxes, net |
|
16,295 |
|
|
184 |
|
||
Distributions to noncontrolling interests |
|
(1,588 |
) |
|
(916 |
) |
||
Other |
|
(6,900 |
) |
|
(3,146 |
) |
||
Net cash used in continuing financing activities |
|
(1,641,061 |
) |
|
(48,249 |
) |
||
Net cash used in discontinued financing activities |
|
- |
|
|
(3,250 |
) |
||
Net cash used in financing activities |
|
(1,641,061 |
) |
|
(51,499 |
) |
||
Effect of exchange rate changes on cash |
|
4,067 |
|
|
4,087 |
|
||
Net (decrease) increase in cash and cash equivalents, including cash classified within current assets held for sale |
|
(244,884 |
) |
|
329,556 |
|
||
Less: cash classified within current assets held for sale |
|
- |
|
|
(75,051 |
) |
||
Net (decrease) increase in cash and cash equivalents |
|
(244,884 |
) |
|
254,505 |
|
||
Cash and cash equivalents at beginning of the period |
|
378,697 |
|
|
124,192 |
|
||
Cash and cash equivalents at end of the period | $ |
133,813 |
|
$ |
378,697 |
|
||
Effect of acquisitions: | ||||||||
Assets acquired, excluding cash | $ |
176,365 |
|
$ |
20,200 |
|
||
Liabilities assumed |
|
(37,350 |
) |
|
(53 |
) |
||
Redeemable noncontrolling interest resulting from an acquisition |
|
- |
|
|
(20,147 |
) |
||
Cash paid for acquisitions, net of cash acquired | $ |
139,015 |
|
$ |
- |
|
||
|
|||||||||||||||||||||||
Operating Statistics |
|||||||||||||||||||||||
(Unaudited, Revenue in thousands) |
|||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
Three Months Ended |
|
Year Ended |
||||||||||||||||||
|
|
|
|
2021 |
|
|
|
2020 |
|
|
% Change |
|
|
2021 |
|
|
|
2020 |
|
|
% Change |
||
Revenue | $ |
591,635 |
|
$ |
534,533 |
|
10.7 |
% |
$ |
2,300,024 |
|
$ |
2,074,456 |
|
10.9 |
% |
|||||||
|
684,984 |
|
|
666,906 |
|
2.7 |
% |
|
2,760,181 |
|
|
2,646,173 |
|
4.3 |
% |
||||||||
Admissions |
|
42,414 |
|
|
42,574 |
|
-0.4 |
% |
|
177,791 |
|
|
171,808 |
|
3.5 |
% |
|||||||
Average Length of Stay (2) |
|
16.1 |
|
|
15.7 |
|
3.1 |
% |
|
15.5 |
|
|
15.4 |
|
0.8 |
% |
|||||||
Revenue per |
$ |
864 |
|
$ |
802 |
|
7.8 |
% |
$ |
833 |
|
$ |
784 |
|
6.3 |
% |
|||||||
Adjusted EBITDA margin (3) |
|
31.3 |
% |
|
33.8 |
% |
-250 bps |
|
29.1 |
% |
|
27.6 |
% |
150 bps | |||||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
28.3 |
% |
|
27.7 |
% |
60 bps |
|
28.3 |
% |
|
26.1 |
% |
220 bps | |||||||||
Revenue | $ |
593,480 |
|
$ |
541,276 |
|
9.6 |
% |
$ |
2,314,394 |
|
$ |
2,089,929 |
|
10.7 |
% |
|||||||
|
686,584 |
|
|
671,840 |
|
2.2 |
% |
|
2,775,061 |
|
|
2,667,762 |
|
4.0 |
% |
||||||||
Admissions |
|
42,691 |
|
|
42,639 |
|
0.1 |
% |
|
179,075 |
|
|
172,277 |
|
3.9 |
% |
|||||||
Average Length of Stay (2) |
|
16.1 |
|
|
15.8 |
|
2.1 |
% |
|
15.5 |
|
|
15.5 |
|
0.1 |
% |
|||||||
Revenue per |
$ |
864 |
|
$ |
806 |
|
7.3 |
% |
$ |
834 |
|
$ |
783 |
|
6.5 |
% |
|||||||
Adjusted EBITDA margin (3) |
|
30.5 |
% |
|
33.5 |
% |
-300 bps |
|
28.4 |
% |
|
27.5 |
% |
90 bps | |||||||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
27.5 |
% |
|
27.4 |
% |
10 bps |
|
27.6 |
% |
|
25.9 |
% |
170 bps |
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | |||||||||||||
(2) Average length of stay is defined as patient days divided by admissions. | |||||||||||||
(3) For the three months and year ended |
|||||||||||||
|
|||||||||||||||||
Reconciliation of Net Income Attributable to |
|||||||||||||||||
(Unaudited) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Year Ended |
|
||||||||||||
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
(in thousands) |
|
||||||||||||||
Net income (loss) attributable to |
$ |
70,278 |
|
$ |
(783,672 |
) |
$ |
190,635 |
|
$ |
(672,132 |
) |
|||||
Net income attributable to noncontrolling interests |
|
1,241 |
|
|
1,131 |
|
|
4,927 |
|
|
2,933 |
|
|||||
Loss from discontinued operations, net of taxes |
|
- |
|
|
842,194 |
|
|
12,641 |
|
|
812,390 |
|
|||||
Provision for income taxes |
|
24,609 |
|
|
16,432 |
|
|
67,557 |
|
|
40,606 |
|
|||||
Interest expense, net |
|
15,573 |
|
|
39,707 |
|
|
76,993 |
|
|
158,105 |
|
|||||
Depreciation and amortization |
|
28,368 |
|
|
24,958 |
|
|
106,717 |
|
|
95,256 |
|
|||||
EBITDA |
|
140,069 |
|
|
140,750 |
|
|
459,470 |
|
|
437,158 |
|
|||||
Adjustments: | |||||||||||||||||
Equity-based compensation expense (a) |
|
12,542 |
|
|
6,246 |
|
|
37,530 |
|
|
22,504 |
|
|||||
Transaction-related expenses (b) |
|
3,458 |
|
|
2,162 |
|
|
12,778 |
|
|
11,720 |
|
|||||
Debt extinguishment costs (c) |
|
- |
|
|
3,962 |
|
|
24,650 |
|
|
7,233 |
|
|||||
Loss on impairment (d) |
|
- |
|
|
4,751 |
|
|
24,293 |
|
|
4,751 |
|
|||||
Adjusted EBITDA | $ |
156,069 |
|
$ |
157,871 |
|
$ |
558,721 |
|
$ |
483,366 |
|
|||||
Adjusted EBITDA margin |
|
26.3 |
% |
|
29.2 |
% |
|
24.1 |
% |
|
23.1 |
% |
|||||
Adjusted EBITDA excluding income from provider relief fund | $ |
138,169 |
|
$ |
125,052 |
|
$ |
540,821 |
|
$ |
450,547 |
|
|||||
Adjusted EBITDA margin excluding income from provider relief fund |
|
23.3 |
% |
|
23.1 |
% |
|
23.4 |
% |
|
21.6 |
% |
|||||
See footnotes on page 13. | |||||||||||||||||
|
||||||||
Reconciliation of Net Income Attributable to |
||||||||
Adjusted Income Attributable to |
||||||||
(Unaudited) |
||||||||
|
|
|
|
|
||||
|
|
Three Months Ended
|
|
Year Ended
|
||||
|
|
(in thousands, except per share amounts) |
||||||
Net income (loss) attributable to |
$ |
70,278 |
|
$ |
190,635 |
|
||
Loss from discontinued operations, net of taxes |
|
- |
|
|
12,641 |
|
||
Adjustments to income: | ||||||||
Transaction-related expenses (b) |
|
3,458 |
|
|
12,778 |
|
||
Debt extinguishment costs (c) |
|
- |
|
|
24,650 |
|
||
Loss on impairment (d) |
|
- |
|
|
24,293 |
|
||
Provision for income taxes |
|
24,609 |
|
|
67,557 |
|
||
Adjusted income from continuing operations before income taxes attributable to |
|
98,345 |
|
|
332,554 |
|
||
Income tax effect of adjustments to income (e) |
|
24,791 |
|
|
87,500 |
|
||
Adjusted income from continuing operations attributable to |
|
73,554 |
|
|
245,054 |
|
||
Income from provider relief fund, net of taxes |
|
(13,044 |
) |
|
(13,044 |
) |
||
Adjusted income from continuing operations attributable to excluding income from provider relief fund |
$ |
60,510 |
|
$ |
232,010 |
|
||
Weighted-average shares outstanding - diluted |
|
91,038 |
|
|
90,793 |
|
||
Adjusted income from continuing operations attributable to per diluted share |
$ |
0.81 |
|
$ |
2.70 |
|
||
Income from provider relief fund, net of taxes, per diluted share |
|
(0.14 |
) |
|
(0.14 |
) |
||
Adjusted income from continuing operations attributable to excluding income from provider relief fund, per diluted share |
$ |
0.67 |
|
$ |
2.56 |
|
||
Three Months Ended
|
Year Ended
|
|||||||
(in thousands, except per share amounts) |
||||||||
Net income (loss) attributable to |
$ |
(783,672 |
) |
$ |
(672,132 |
) |
||
Loss from discontinued operations, net of taxes |
|
842,194 |
|
|
812,390 |
|
||
Adjustments to income: | ||||||||
Transaction-related expenses (b) |
|
2,162 |
|
|
11,720 |
|
||
Debt extinguishment costs (c) |
|
3,962 |
|
|
7,233 |
|
||
Loss on impairment (d) |
|
4,751 |
|
|
4,751 |
|
||
Provision for income taxes |
|
16,432 |
|
|
40,606 |
|
||
Adjusted income from continuing operations before income taxes attributable to |
|
85,829 |
|
|
204,568 |
|
||
Adjusted income from discontinued operations before income taxes |
|
31,483 |
|
|
86,258 |
|
||
Adjusted income before income taxes attributable to |
|
117,312 |
|
|
290,826 |
|
||
Income tax effect of adjustments to income (e) |
|
16,124 |
|
|
44,496 |
|
||
Adjusted income attributable to |
|
101,188 |
|
|
246,330 |
|
||
Income from provider relief fund, net of taxes |
|
(23,915 |
) |
|
(23,915 |
) |
||
Adjusted income attributable to provider relief fund |
$ |
77,273 |
|
$ |
222,415 |
|
||
Weighted-average shares outstanding - diluted |
|
89,233 |
|
|
88,595 |
|
||
Adjusted income attributable to |
$ |
1.13 |
|
$ |
2.78 |
|
||
Income from provider relief fund, net of taxes, per diluted share |
|
(0.27 |
) |
|
(0.27 |
) |
||
Adjusted income attributable to provider relief fund, per diluted share |
$ |
0.86 |
|
$ |
2.51 |
|
(4) For the three months and year ended |
||||
See footnotes on page 13. |
|
|||||||||||||||||
Discontinued Operations Supplemental Financial Information |
|||||||||||||||||
(Unaudited) |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
Statements of Discontinued Operations |
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months
Ended |
|
Year Ended
|
|
||||||||||||
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
(in thousands) |
|
||||||||||||||
Revenue | $ |
- |
|
$ |
301,996 |
|
$ |
62,520 |
|
$ |
1,119,768 |
|
|||||
Salaries, wages and benefits |
|
- |
|
|
166,620 |
|
|
35,937 |
|
|
632,134 |
|
|||||
Professional fees |
|
- |
|
|
35,027 |
|
|
6,815 |
|
|
127,291 |
|
|||||
Supplies |
|
- |
|
|
10,011 |
|
|
2,217 |
|
|
38,285 |
|
|||||
Rents and leases |
|
- |
|
|
12,890 |
|
|
2,509 |
|
|
47,748 |
|
|||||
Other operating expenses |
|
- |
|
|
27,852 |
|
|
6,682 |
|
|
113,534 |
|
|||||
Depreciation and amortization |
|
- |
|
|
19,196 |
|
|
- |
|
|
74,935 |
|
|||||
Interest expense, net |
|
- |
|
|
(1,083 |
) |
|
10 |
|
|
(417 |
) |
|||||
Loss on sale |
|
(764 |
) |
|
867,324 |
|
|
13,490 |
|
|
867,324 |
|
|||||
Loss on impairment |
|
- |
|
|
- |
|
|
- |
|
|
20,239 |
|
|||||
Transaction-related expenses |
|
- |
|
|
984 |
|
|
6,265 |
|
|
8,719 |
|
|||||
Total expenses |
|
(764 |
) |
|
1,138,821 |
|
|
73,925 |
|
|
1,929,792 |
|
|||||
Income (loss) from discontinued operations before income taxes |
|
764 |
|
|
(836,825 |
) |
|
(11,405 |
) |
|
(810,024 |
) |
|||||
Provision for (benefit from) income taxes |
|
764 |
|
|
5,369 |
|
|
1,236 |
|
|
2,366 |
|
|||||
Income (loss) from discontinued operations, net of taxes |
|
- |
|
|
(842,194 |
) |
|
(12,641 |
) |
|
(812,390 |
) |
|||||
Reconciliation of Income (Loss) from Discontinued Operations to
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months
Ended |
|
Year Ended
|
|
||||||||||||
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
(in thousands) | |||||||||||||||||
Income (loss) from discontinued operations, net of taxes | $ |
- |
|
$ |
(842,194 |
) |
$ |
(12,641 |
) |
$ |
(812,390 |
) |
|||||
Adjustments to income: | |||||||||||||||||
Transaction-related expenses (b) |
|
- |
|
|
984 |
|
|
6,265 |
|
|
8,719 |
|
|||||
Loss on sale (f) |
|
(764 |
) |
|
867,324 |
|
|
13,490 |
|
|
867,324 |
|
|||||
Loss on impairment (d) |
|
- |
|
|
- |
|
|
- |
|
|
20,239 |
|
|||||
Provision for (benefit from) income taxes |
|
764 |
|
|
5,369 |
|
|
1,236 |
|
|
2,366 |
|
|||||
Adjusted income from discontinued operations before income taxes | $ |
- |
|
$ |
31,483 |
|
$ |
8,350 |
|
$ |
86,258 |
|
|||||
See footnotes on page 13. | |||||||||||||||||
Footnotes | |||||||||||
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows: | |||||||||||
• EBITDA: net income (loss) attributable to |
|||||||||||
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction-related expenses, debt extinguishment costs and loss on impairment. | |||||||||||
• Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund. | |||||||||||
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue. | |||||||||||
• Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue. | |||||||||||
• Adjusted income from continuing operations before income taxes attributable to |
|||||||||||
• Adjusted income from continuing operations attributable to |
|||||||||||
• Adjusted income from continuing operations attributable to |
|||||||||||
• Adjusted income from discontinued operations before income taxes: Loss from discontinued operations, net of taxes, adjusted for transaction-related expenses, loss on sale, loss on impairment and provision for (benefit from) income taxes. | |||||||||||
• Adjusted income attributable to |
|||||||||||
• Adjusted income attributable to |
|||||||||||
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in |
|||||||||||
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. | |||||||||||
(a) Represents the equity-based compensation expense of Acadia. | |||||||||||
(b) Represents transaction-related expenses incurred by Acadia primarily related to termination, restructuring, strategic review, acquisition and other similar costs. | |||||||||||
(c) Represents debt extinguishment costs recorded during the first quarter of 2021 in connection with the redemption of the |
|||||||||||
(d) The Company opened a 260-bed replacement hospital in |
|||||||||||
(e) Represents the income tax effect of adjustments to income based on tax rates of |
|||||||||||
(f) For 2020, represents the loss on sale, including a non-cash goodwill impairment charge of |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005992/en/
Vice President, Investor Relations
(615) 861-6000
Source:
FAQ
What were Acadia Healthcare's Q4 2021 financial results?
What is Acadia Healthcare's financial guidance for 2022?
What strategic initiatives did Acadia Healthcare announce?